Royalties from the CD38-targeted antibody therapeutic Darzalex (daratumumab) were the main source of revenue for Genmab A/S in the 2017 first quarter. Developed by Genmab and licensed to Janssen Biotech Inc, the product is approved for the treatment of multiple myeloma.
